Pliant Therapeutics Shares Plummet Following Clinical Trial Setback

Pliant Therapeutics Inc. is facing a severe market downturn as its share price experiences significant erosion. This steep decline comes in direct response to the company’s decision to terminate its flagship development program, reflecting profound disappointment among its investor base.

The company’s equity witnessed a substantial drop of 4.68% in a single trading session, falling from $1.71 to close at $1.63. This price movement solidifies a pronounced downward trend that is clearly visible across key moving averages. Considerable selling pressure has emerged, highlighting deep-seated market uncertainty surrounding the stock’s near-term prospects.

Clinical Program Termination Sends Shockwaves

In a major strategic shift during August 2025, Pliant Therapeutics halted development of its bexotegrast program for idiopathic pulmonary fibrosis (IPF). This decisive Read more...

de | US7291391057 | PLIANT | boerse | 68166181 |